Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The firm is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.
最新の財務諸表(Form-10K)によると、Aethlon Medical Incの総資産は$0で、純損失は$0です。
AEMDの主要な財務比率は何ですか?
Aethlon Medical Incの流動比率は0、純利益率は0、1株当たり売上高は$0です。
Aethlon Medical Incの収益はセグメントまたは地域別にどのように分けられていますか?
Aethlon Medical Inc の最大収益セグメントは Zinc-based Battery Energy Storage Solutions で、最新の利益発表における収益は 111,979,000 です。地域別に見ると、United States が Aethlon Medical Inc の主要市場であり、収益は 92,685,000 です。